NICE reverses decision to reject novel osteoporosis drug in final guidelines

摘要

The National Institute for Health and Care Excellence (NICE) has overturned its provisional decision not to recommend the first new osteoporosis medicine it has considered for more than a decade. In its final final.technology appraisal document(https://www.nice.org.uk/guidance/gid-tal0828/documents/final-appraisal-determination-document). published on 1 April 2022, NICE recommends romosozumab as an option for treating severe osteoporosis in people after menopause who are at high risk of fracture, and who meet certain criteria.